Lytix Biopharma ASA (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 9.58
-0.22 (-2.24%)
Nov 13, 2026, 4:25 PM CET
Lytix Biopharma ASA Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 13.25 | 10.6 | 130.79 | 27.37 | 94.55 | 197.28 |
Short-Term Investments | 54.01 | - | - | 23.18 | 50.61 | - |
Trading Asset Securities | - | 61.76 | - | - | - | - |
Cash & Short-Term Investments | 67.26 | 72.36 | 130.79 | 50.55 | 145.16 | 197.28 |
Cash Growth | -25.27% | -44.68% | 158.75% | -65.18% | -26.42% | 593.43% |
Accounts Receivable | 7.16 | 0.35 | 0.46 | - | - | - |
Other Receivables | - | 5.81 | 12.1 | 12.12 | 6 | 5.13 |
Receivables | 7.16 | 6.15 | 12.56 | 12.12 | 6 | 5.13 |
Prepaid Expenses | - | 0.93 | 0.55 | 0.66 | 0.74 | 0.55 |
Other Current Assets | - | - | - | 0 | - | - |
Total Current Assets | 74.42 | 79.44 | 143.9 | 63.33 | 151.89 | 202.96 |
Property, Plant & Equipment | 1.4 | 2.09 | 2.63 | 0.55 | 1.38 | 2.14 |
Other Long-Term Assets | - | 0 | - | - | 0 | - |
Total Assets | 75.82 | 81.52 | 146.54 | 63.87 | 153.27 | 205.1 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.72 | 6.38 | 5.02 | 3.57 | 7 | 1.48 |
Accrued Expenses | - | 6.21 | 24.44 | 2.38 | 2.11 | 3.77 |
Current Portion of Leases | 1.07 | 0.98 | 0.76 | 0.45 | 0.87 | 0.83 |
Current Income Taxes Payable | - | 1.07 | 1.19 | 1.36 | 0.95 | 2.03 |
Other Current Liabilities | 4.91 | 3.92 | 5.36 | 4.74 | 6.83 | 6.06 |
Total Current Liabilities | 11.7 | 18.55 | 36.76 | 12.51 | 17.76 | 14.17 |
Long-Term Leases | 0.45 | 1.22 | 1.88 | 0.04 | 0.48 | 1.34 |
Other Long-Term Liabilities | - | - | -0 | - | - | - |
Total Liabilities | 12.15 | 19.77 | 38.64 | 12.56 | 18.24 | 15.51 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 7.69 | 6.83 | 6.82 | 4.01 | 4.01 | 3.87 |
Additional Paid-In Capital | 55.98 | 54.92 | 101.08 | 47.31 | 131.03 | 185.72 |
Comprehensive Income & Other | - | 0 | - | - | - | -0 |
Shareholders' Equity | 63.67 | 61.75 | 107.89 | 51.32 | 135.03 | 189.59 |
Total Liabilities & Equity | 75.82 | 81.52 | 146.54 | 63.87 | 153.27 | 205.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.51 | 2.2 | 2.64 | 0.49 | 1.34 | 2.17 |
Net Cash (Debt) | 65.75 | 70.16 | 128.15 | 50.06 | 143.81 | 195.11 |
Net Cash Growth | -24.92% | -45.25% | 156.01% | -65.19% | -26.29% | 585.80% |
Net Cash Per Share | - | 1.03 | 2.37 | 1.25 | 3.63 | 5.88 |
Filing Date Shares Outstanding | - | 68.26 | 68.26 | 40.07 | 40.07 | 40.07 |
Total Common Shares Outstanding | - | 68.26 | 68.16 | 40.07 | 40.07 | 38.74 |
Working Capital | 62.72 | 60.88 | 107.14 | 50.81 | 134.13 | 188.8 |
Book Value Per Share | - | 0.90 | 1.58 | 1.28 | 3.37 | 4.89 |
Tangible Book Value | 63.67 | 61.75 | 107.89 | 51.32 | 135.03 | 189.59 |
Tangible Book Value Per Share | - | 0.90 | 1.58 | 1.28 | 3.37 | 4.89 |
Machinery | - | 0.2 | 0.2 | 0.2 | 0.15 | - |